Sodium risedronate
Sodium risedronate structure
|
Common Name | Sodium risedronate | ||
|---|---|---|---|---|
| CAS Number | 115436-72-1 | Molecular Weight | 305.094 | |
| Density | N/A | Boiling Point | 692.3ºC at 760 mmHg | |
| Molecular Formula | C7H10NNaO7P2 | Melting Point | 252-262°C | |
| MSDS | Chinese | Flash Point | 372.5ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
Arch. Pharm. Res. 37(12) , 1560-9, (2014) Risedronate is widely used clinically to treat osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects. This study... |
|
|
Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.
Biochim. Biophys. Acta 1841(7) , 977-86, (2014) 2,3-Oxidosqualene is an intermediate in cholesterol biosynthesis and 2,3:22,23-dioxidosqualene act as the substrate for an alternative pathway that produces 24(S),25-epoxycholesterol which effects cholesterol homeostasis. In light of our previous findings con... |
|
|
Risedronate increases osteoblastic differentiation and function through connexin43.
Biochem. Biophys. Res. Commun. 432(1) , 152-6, (2013) Bisphosphonates are potent antiresorptive drugs which have antifracture efficacy by reducing bone turnover rate and increasing bone mineral density. In addition to inhibiting osteoclast function, bisphosphonates have been reported to also promote survival of ... |
|
|
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
J. Bone Miner. Metab. 31 , 206-211, (2013) This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four g... |
|
|
Squamous metaplasia of the conjunctiva: a previously unrecognized adverse effect of risedronate sodium.
JAMA Ophthalmol. 131(2) , 249-51, (2013)
|
|
|
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Lancet Oncol. 15(13) , 1460-8, (2014) Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for prevention of reduction in bone mineral density (BMD) after 3 years... |
|
|
Risk of atypical femoral fracture during and after bisphosphonate use.
Acta Orthop. 86(1) , 100-7, (2015) Use of bisphosphonates in women is associated with higher risk of atypical femoral fractures. The risk in terms of timing of use and type of bisphosphonate, and in men, remains unclear.We reviewed radiographs of 5,342 Swedish women and men aged 55 years or mo... |
|
|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
MMW Fortschr. Med. 154 Suppl 1 , 10-21, (2012) The therapeutic strategy for the reduction of fracture risk in osteoporosis should not only aim to increase bone strength, but should also improve muscle function and reduce falls without increasing the risk of significant side effects. Since 2008 a combinati... |
|
|
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
J. Biomed. Nanotechnol. 9(2) , 193-201, (2013) A superior drug formulation capable of achieving efficient osteogenesis is in imperative demand for the treatment of osteoporosis. In the present study we investigated the potential of using novel risedronate-hydroxyapatite (HA) nanoparticle based formulation... |
|
|
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Rheumatology (Oxford.) 52(6) , 1058-69, (2013) Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) ver... |